Data / Form D filings / OncoResponse, Inc
OncoResponse, Inc: Form D filings
OncoResponse, Inc, a biotechnology company in Houston, TX, filed 7 Form D notices with the SEC between 2015 and 2025. The latest, on May 6, 2025, reports $6 million sold of an offering with no set size to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 609 MAIN STREET, SUITE 4200, Houston, TX, 77002
- Phone
- (206) 805-1600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1655774
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 6, 2025 | New notice | Indefinite | $5,999,138 | 9 | Apr 21, 2025 | sec.gov | |
| May 12, 2023 | New notice | $40,000,000 | $13,915,153 | $26,084,847 | 13 | May 1, 2023 | sec.gov |
| Mar 31, 2021 | New notice | $60,000,000 | $40,625,995 | $19,374,005 | 14 | Mar 17, 2021 | sec.gov |
| Sep 6, 2018 | New notice | $39,999,995 | $18,999,999 | $20,999,996 | 12 | Aug 23, 2018 | sec.gov |
| Mar 23, 2017 | Amendment | $34,044,454 | $29,499,000 | $4,545,454 | 12 | Sep 30, 2015 | sec.gov |
| May 26, 2016 | Amendment | $28,224,448 | $19,499,000 | $8,725,448 | 8 | Sep 30, 2015 | sec.gov |
| Oct 15, 2015 | New notice | $28,224,448 | $16,499,000 | $11,725,448 | 7 | Sep 30, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Sean A. McCarthy | Director | |
| Roberto D. De Ponti | Director | |
| Alice J. Bexon | Executive Officer | |
| Steven D. Gillis | Director | |
| Clifford J. Stocks | Director, Executive Officer | |
| Kamal D. Puri | Executive Officer | |
| Carol D. Gallagher | Director | |
| John A. McKearn | Director | |
| Chris D. Russell | Executive Officer | |
| Wende D. Hutton | Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of May 5, 2025 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what OncoResponse, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.